Solventum’s Quarterly Earnings Preview: What You Need to Know

With a market cap of $14.5 billion,  Solventum Corporation (SOLV) is a global healthcare company. The Maplewood, Minnesota-based company develops and manufactures medical and surgical products, advanced wound care solutions, dental and orthodontic products, and healthcare software designed to improve patient outcomes and streamline clinical workflows. 

The leading global healthcare company is expected to announce its fiscal third-quarter earnings for 2026 after the market closes on Thursday, Nov. 5. Ahead of the event, analysts expect SOLV to report a profit of $1.35 per share on a diluted basis, down 10% from $1.50 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. 

The growth prospects shine brighter for the long term. For the current year, analysts expect SOLV to report EPS of $7.21, up 18% from $6.11 in fiscal 2025. Its EPS is expected to rise marginally year over year to $7.23 in fiscal 2027.

SOLV stock has outperformed the S&P 500 Index’s ($SPX) 13% gains over the past 52 weeks, with shares up 20.1% during this period. However, it has underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 22.8% gains over the same time frame.

On Oct. 19, Solventum announced that the FDA had granted 510(k) clearance for the combined use of its V.A.C. Therapy and Restrata Synthetic Electrospun Fiber Matrix to treat complex wounds. The combination pairs Restrata’s structural support for tissue repair with V.A.C. Therapy’s negative-pressure technology to promote healing, potentially reducing dressing changes and streamlining clinical workflows. Its shares rose 1.6% in the next trading session. 

Analysts’ consensus opinion on SOLV stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 16 analysts covering the stock, eight advise a “Strong Buy” rating, six give a “Hold,” and two recommend a “Strong Sell.” SOLV’s average analyst price target is $93,93, indicating a potential upside of 9.5% from the current levels. 

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.